leucovorin calcium

P2, N=155, Active, not recruiting, University Health Network, Toronto | Trial primary completion date: Apr 2026 --> Dec 2026

CALLY and HALP scores are effective predictors of chemotherapy response and survival in CRC patients with pulmonary metastases receiving FOLFOX. Their combined application enhances risk stratification and may assist in individualized treatment decision-making.

P2, N=150, Not yet recruiting, Verastem, Inc.

In this large real-world cohort, leucovorin significantly improved survival in patients with metastatic colorectal cancer receiving fluorouracil but was associated with increased treatment-related toxicity. These findings support the continued use of leucovorin as a key component of fluorouracil-based chemotherapy regimens.

P2/3, N=172, Not yet recruiting, Gruppo Oncologico Del Nord Ovest

The CCL3/CCR5 axis drives Oxa resistance in GC by boosting tumor cell survival and fostering immunosuppressive M2 macrophages. Targeting this pathway may offer a strategy to overcome chemoresistance in GC.

P2, N=24, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2029 --> Mar 2031 | Trial primary completion date: Dec 2029 --> Mar 2028 | Recruiting --> Active, not recruiting

P2, N=143, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: May 2027 --> Nov 2027 | Trial primary completion date: Jul 2026 --> Dec 2026

We report a case of metastatic CRC that achieved CR following second-line treatment with FOLFIRI plus ramucirumab after disease progression on first-line FOLFOX plus panitumumab therapy...In the present case, a watch-and-wait strategy was selected to prioritize organ preservation. Given the lack of consensus, further investigation is required to define the optimal strategy for patients achieving CR.

P2, N=27, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N=40 --> 27 | Trial completion date: Sep 2027 --> Jun 2036 | Trial primary completion date: Apr 2027 --> Jun 2036

P2, N=31, Recruiting, Guang'anmen Hospital of China Academy of Chinese Medical Sciences

This phase II study (ChiCTR2300077718) aimed to assess the efficacy and safety of balloon-occluded HAIC (bHAIC) based on the FOLFOX (oxaliplatin plus fluorouracil and leucovorin) regimen (bHAIC-FO) in unresectable HCC. bHAIC-FO demonstrates encouraging efficacy and acceptable safety profiles in unresectable HCC treatment, particularly in treatment-naive patients. www.chictr.org.cn, identifier ChiCTR2300077718.